Allarity Therapeutics Shares Are Trading Higher After the Company Announced That Stenoparib Shows a Clear Clinical Benefit, Leading to Early Conclusion of the Phase 2 Trial in Advanced Ovarian Cancer
Alarity Therapeutics宣布Stenoparib显示出明显的临床益处，导致晚期卵巢癌的2期试验提前结束，此后，Alarity Therapeutics的股价走高